Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

MADRID — In the past week, a GSK cancer drug picked up an approval for another tumor type, the company unveiled the first data from a global study of a promising next-generation chemotherapy, and a medicine that the firm has licensed got the limelight in a presidential session at a major oncology conference here. 

GSK is also awaiting another expected approval in the coming weeks, this time for a new lung cancer drug. 

It’s a good run considering GSK was out of oncology a decade ago.

1. 

   Europe Correspondent

   Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.